Latest Hotspot

Weekly Islatravir-Lenacapavir Combo Maintains Viral Control in Phase 2 Trial

7 March 2024
3 min read

Gilead Sciences, Inc. and Merck, known as MSD outside of the United States and Canada have publicly shared the outcomes of a Phase 2 clinical trial. This study focused on the assessment of a novel treatment regimen which includes islatravir, a nucleoside reverse transcriptase translocation inhibitor currently under investigation, in combination with lenacapavir, an innovative agent classified as a capsid inhibitor.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

These freshly revealed findings were disclosed in an oral segment at the 31st Conference on Retroviruses and Opportunistic Infections. Before this engaging oral exposition, a press briefing by CROI highlighted the crucial outcomes.

After a 24-week period, the test combination under investigation successfully sustained elevated levels of reduced viral activity, which constitutes an ancillary goal of this research. Evaluation of the main objective revealed that, at week 24, a subject receiving islatravir alongside lenacapavir presented with a viral count exceeding 50 copies/mL; however, by week 30, the virus was undetectable in the individual while continuing the same treatment regimen.

The robust antiretroviral efficacy, fused with the pharmacokinetic characteristics of islatravir and lenacapavir, advocate for the advancement of this innovative once-a-week oral regimen for further investigations. Daily oral treatments administered via a single pill have significantly advanced HIV treatment, yet therapies that require less frequent administration could contribute to surmounting the hurdles of adherence and discrimination, among other issues, for certain individuals on daily antiretroviral therapies.

"Tailoring HIV treatments to individual needs is essential - the exploration of weekly treatment alternatives could address personal requirements, aiming for the enhancement of durable outcomes for those living with HIV," remarked Jared Baeten, who is the Vice President of HIV Clinical Development at Gilead Sciences, with both an MD and a PhD. "The encouraging data shared at CROI takes us a step nearer to achieving an array of choices that might revolutionize the field of HIV therapy."

Islatravir, as a solo agent or when paired with lenacapavir, remains in the experimental stage and lacks authorization across the globe. The efficacy and security of the islatravir and lenacapavir duo are yet to be certified.

Lenacapavir, sold under the brand name Sunlenca, has received authorization in several countries including Australia, Canada, the European Union, Israel, Japan, Switzerland, United Arab Emirates, United Kingdom, and the United States, specifically for treating individuals with HIV that shows resistance to multiple drugs, as part of a combined antiretroviral therapy.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of March 7, 2024, there are 1 investigational drugs for the HIV-1 RT and capsid target, including 1 indications,2 R&D institutions involved, with related clinical trials reaching 8, and as many as 1 patents.

Islatravir/Lenacapavir is a small molecule drug that shows promise in targeting HIV-1 RT and capsid. With its active indication being HIV infections and its current status in Phase 2 of development, this drug has the potential to address a significant unmet medical need in the field of biomedicine. Further clinical trials and research will be necessary to determine its safety and efficacy, but the initial information suggests that Islatravir/Lenacapavir could be a valuable addition to the treatment options available for HIV infections.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Targeting the Amylin Receptor for Obesity Weight Reduction
Targeting the Amylin Receptor for Obesity Weight Reduction
7 March 2024
Islet Amyloid Polypeptide (IAPP), also known as amylin, is a peptide hormone composed of 37 amino acids, secreted by the pancreatic beta-cells.
Read →
Sandoz Obtains US Health Regulator's Green Light for Unique Denosumab Bioequivalents
Latest Hotspot
4 min read
Sandoz Obtains US Health Regulator's Green Light for Unique Denosumab Bioequivalents
7 March 2024
Sandoz announced that its products Wyost® and Jubbonti®, both containing denosumab-bbdz, have been approved by the US FDA.
Read →
Synapse Simplified: How to Find Clotrimazole Information
Drug Insights
2 min read
Synapse Simplified: How to Find Clotrimazole Information
7 March 2024
Clotrimazole, a diminutive molecule of pharmacological relevance, exerts its influence as an astoundingly powerful CYP51A1 inhibitor.
Read →
Innate Pharma Reveals Early Research on Nectin-4 Targeting Agent IPH45 at 2024 AACR Event
Latest Hotspot
3 min read
Innate Pharma Reveals Early Research on Nectin-4 Targeting Agent IPH45 at 2024 AACR Event
7 March 2024
Innate Pharma SA has declared that its pioneering research on the preclinical compound IPH45, a unique Antibody Drug Conjugate that targets Nectin-4 by inhibiting topoisomerase I.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.